Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 3 studies. This list may not include all unresolved or historical entries.

  • CP-870,893Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • CP-870,893Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • CP-870,893Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 1
2
67%
Early Phase 1
1
33%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 12 (66.7%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

NCT02225002
completedphase_1

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

NCT01456585
completedearly_phase_1

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

NCT02157831

Clinical Trials (3)

Showing 3 of 3 trials
NCT02225002Phase 1

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Completed
NCT01456585Phase 1

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Completed
NCT02157831Early Phase 1

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Completed

All 3 trials loaded

Drug Details

Intervention Type
Varies by study
Total Trials
3